GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Net Issuance of Preferred Stock

Telesis Bio (Telesis Bio) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Telesis Bio's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. The number is 0, which means that Telesis Bio has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Telesis Bio's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Telesis Bio Net Issuance of Preferred Stock Historical Data

The historical data trend for Telesis Bio's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio Net Issuance of Preferred Stock Chart

Telesis Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
- - - - 18.41

Telesis Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Telesis Bio Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telesis Bio Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Telesis Bio's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Telesis Bio (Telesis Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
NSYS LNSR RDGL NMTC RMSL MODD PETV COCH PAVM SSKN ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121
Website
https://www.telesisbio.com
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.
Executives
Gregory J. Herrema director 355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers 10 percent owner GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p. 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider director, 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister director, 10 percent owner 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler officer: Chief Legal Officer C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson officer: Chief Technology Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson director, 10 percent owner, officer: President & CEO C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser officer: Chief Operating Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814